MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
about
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.Oncogenes: The Passport for Viral Oncolysis Through PKR InhibitionThe evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinibTherapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With ImmunotherapyCombination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done YetGenomically driven precision medicine to improve outcomes in anaplastic thyroid cancerDeciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicinePathways and therapeutic targets in melanomaTargeting cancer with kinase inhibitorsTumour heterogeneity and the evolution of polyclonal drug resistanceBeyond BRAF: where next for melanoma therapy?Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesTargeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondDeconstructing the role of the ECM microenvironment on drug efficacy targeting MAPK signaling in a pre-clinical platform for cutaneous melanoma.Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAFDetailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in MelanomaNon-genomic and Immune Evolution of Melanoma Acquiring MAPKi ResistanceMutant HRAS as novel target for MEK and mTOR inhibitorsStochastic modeling suggests that noise reduces differentiation efficiency by inducing a heterogeneous drug response in glioma differentiation therapyManaging leptomeningeal melanoma metastases in the era of immune and targeted therapy.Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Assessing the clinical utility of cancer genomic and proteomic data across tumor types.Discrepant alterations in main candidate genes among multiple primary melanomasReview of current methods, applications, and data management for the bioinformatics analysis of whole exome sequencing.Integrin β1 activation induces an anti-melanoma host responseClinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model.New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapyActivated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.Change or die: targeting adaptive signaling to kinase inhibition in cancer cells.Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorPerturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.Genotyping of cutaneous melanoma.Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma modelsOvercoming resistance to BRAF inhibition in BRAF-mutated metastatic melanomaComparison of custom capture for targeted next-generation DNA sequencing
P2860
Q24315032-B1222C48-0B0F-4A38-BFBC-A830009BD3C9Q26739777-616F2848-F4C9-459C-AE30-4F928E832016Q26744335-16D789AB-70F7-4BBD-8010-16D7B25B8752Q26782222-07B0F0EE-455F-4E8A-A888-3B23F764B098Q26796309-CADE3BEF-2E17-4472-9F7A-8AB6B5586593Q26799864-82112B4A-5583-489D-AA55-0BB9A30B5ADAQ26820880-46CC846A-27A7-4221-9EDA-F1265385751BQ26825186-BEF916CF-4F33-452F-B1F5-5C3A25417E3FQ26865736-3937588D-EFAF-4110-A319-42012E44ACA0Q26865765-34747BAD-41EB-4B6B-9E17-B33D7AF08F90Q26866803-4632FAB1-3E20-421A-9707-FBD9EAF7171DQ27006853-6AB4C48D-03D0-4B34-B9BF-41745D88D21AQ27015224-9350FDF1-34D2-4662-80D7-D191EDA3DE5EQ27026323-632ABC16-3D58-4CFE-85A8-FD5BB930B8AEQ27329810-8F4BC5E7-2FAB-485F-8631-4BC28823FFBEQ27852994-23506A56-5231-4CC8-826E-669341E1BECCQ27853045-5C61BC9C-9869-4BA3-8E99-BDF04BB8CC7DQ27853105-10074BED-37AD-4905-8DF5-FDE803D76AEDQ27853202-5DB5C86C-0D9F-4970-BDA1-3FD5F5CF6042Q27853210-2E248E3A-D30A-433E-9BC9-5A9EAEEAFAE4Q27853238-187E4DD5-A84B-434F-9B60-5E1442CE7581Q28830465-BD8A1BC6-F382-4687-A5BE-D3DF10213E7AQ30251581-D1F33506-5AD4-4774-A5C0-9D6D10C03563Q30277902-6B7E8648-0351-4CF2-8D8B-46A1DA11A5A0Q30458424-80A711C7-FB1A-41C0-9C0E-04C3E63DF568Q30487077-AA3F4620-52D9-4423-8D9C-EDE8F76C1633Q30578299-0AA6FBA9-B6CD-488D-A06C-A9CED3651CD2Q30857788-3B1D8EF8-DA8D-4A27-BFB7-09FC88192745Q33610627-4C31E02C-B5EB-4F41-B7B5-005E1B258147Q33767369-64258373-8D09-466D-A285-773249D0A297Q33824552-2A4144F2-C477-4F3B-A60D-6A2A70703B4AQ33884726-7A200A22-A7DF-4BDE-8159-CBACC3A5D9D3Q34132936-F53EA263-DAA6-4F3D-8C11-74D900EBC307Q34225871-68EBB434-6D07-4746-8D6E-BD44713AABE4Q34484174-698D90DF-F838-48D6-90D5-02B11EC6BAE9Q34489987-DC19D334-8291-478E-8B44-9EC6F64FED78Q34667738-0D8AB332-8356-49C9-98D5-46FE1A56BAA1Q34677194-36DFDA44-FD79-4655-98B1-C4B7F2EBAEC4Q34786402-D9EA486D-C13A-4967-B6F1-D1B978B58FFFQ34786626-8CBBDE0E-7AE4-4FD0-921E-1C6D032C7AAC
P2860
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
MAP kinase pathway alterations ...... o combined RAF/MEK inhibition.
@en
MAP kinase pathway alterations ...... o combined RAF/MEK inhibition.
@nl
type
label
MAP kinase pathway alterations ...... o combined RAF/MEK inhibition.
@en
MAP kinase pathway alterations ...... o combined RAF/MEK inhibition.
@nl
altLabel
MAP kinase pathway alterations ...... to combined RAF/MEK inhibition
@en
prefLabel
MAP kinase pathway alterations ...... o combined RAF/MEK inhibition.
@en
MAP kinase pathway alterations ...... o combined RAF/MEK inhibition.
@nl
P2093
P2860
P50
P1433
P1476
MAP kinase pathway alterations ...... o combined RAF/MEK inhibition.
@en
P2093
Aaron McKenna
Cory M Johannessen
Daniel J Treacy
Danielle Perrin
Deborah N Farlow
Dennie T Frederick
Dennis C Friedrich
Donald P Lawrence
Eliezer M Van Allen
Eran Hodis
P2860
P356
10.1158/2159-8290.CD-13-0631
P407
P577
2013-11-21T00:00:00Z